The President and CSO of Corbus Pharmaceuticals is Exercising Options


Today it was reported that the President and CSO of Corbus Pharmaceuticals (CRBP), Mark Tepper, exercised options to buy 10,000 CRBP shares at $1.00 a share, for a total transaction value of $10K.

Following Mark Tepper’s last CRBP Buy transaction on November 25, 2014, the stock climbed by 3.1%.

See today’s analyst top recommended stocks >>

Based on Corbus Pharmaceuticals’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $1.09 million and GAAP net loss of $14.6 million. In comparison, last year the company earned revenue of $796.3K and had a GAAP net loss of $6.97 million. Currently, Corbus Pharmaceuticals has an average volume of 627.4K. The Company has a Price to Book ratio of 8.0908.

Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $27.50, reflecting a 353.0% upside. Starting in December 2017, CRBP received 23 Buy ratings in a row. Four different firms, including B.Riley FBR and Cantor Fitzgerald, currently also have a Buy rating on the stock.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts